This suggests a window between a rise in Aβ levels and the associated rise of toxic tau levels which must be considered a critical time to address underlying pathological sequelae of AD, specifically cognitive impairment, with Aβ-targeted reduction. This evidence concerns the gene MAPT and Alzheimer disease.